

NOTICE OF NO AUDITOR REVIEW

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that the financial statements have not been reviewed by an auditor.

The accompanying unaudited interim financial statements of Akumin Inc. (the "**Company**") for the three- and nine-months ended September 30, 2020 and 2019 have been prepared by management and approved by the Audit Committee and Board of Directors of the Company.

The Company's independent auditor has not performed a review of the unaudited interim financial statements of the Company for the comparative period (being the three- and nine-months ended September 30, 2019) in accordance with the standards applicable to the Company's interim financial statements.

Akumin Inc.

Condensed Consolidated
Financial Statements
(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

Akumin Inc.

Table of Contents

	<u>Page</u>
Condensed Consolidated Financial Statements (Unaudited)	
Condensed Consolidated Balance Sheets	1
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)	2
Condensed Consolidated Statements of Changes in Equity	3
Condensed Consolidated Statements of Cash Flows	4
Notes to Condensed Consolidated Financial Statements	5 – 32

Akumin Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(expressed in US dollars unless otherwise stated)

	September 30, 2020 \$	December 31, 2019 \$
Assets		
Current assets		
Cash	27,356,544	23,388,916
Accounts receivable	98,994,756	82,867,225
Prepaid expenses and other current assets	2,863,276	3,927,949
	<u>129,214,576</u>	<u>110,184,090</u>
Security deposits and other assets	2,896,928	1,967,053
Property and equipment (note 5)	77,972,262	75,938,590
Operating lease right-of-use assets (note 4)	132,130,890	126,675,770
Goodwill	360,603,613	358,802,534
Intangible assets	7,418,216	9,432,480
Total assets	<u>710,236,485</u>	<u>683,000,517</u>
Liabilities		
Current liabilities		
Accounts payable and accrued liabilities	32,340,619	26,262,225
Finance lease liabilities (note 7)	2,907,779	1,789,995
Operating lease liabilities (right-of-use) (notes 4 and 7)	9,470,609	9,276,298
Senior loans payable (note 8)	4,380,668	3,705,952
Earn-out liability (note 6)	9,377,106	7,529,962
	<u>58,476,781</u>	<u>48,564,432</u>
Finance lease liabilities (note 7)	10,545,992	6,625,409
Operating lease liabilities (right-of-use) (notes 4 and 7)	127,946,276	119,773,692
Senior loans payable (note 8)	340,732,549	336,276,370
Derivative financial instruments (note 8)	4,905,871	951,702
Subordinated notes payable – earn-out (note 9)	200,000	184,485
Earn-out liability (note 6)	-	7,304,105
Accrued payroll taxes (note 18)	1,516,808	-
Deferred tax liability	4,862,444	6,256,820
Total liabilities	<u>549,186,721</u>	<u>525,937,015</u>
Shareholders' equity		
Additional paid-in capital (common shares no par value, unlimited authorized number of shares, 70,178,428 and 69,840,928 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively) (note 10)	160,607,530	158,881,120
Deficit	<u>(4,934,547)</u>	<u>(6,361,767)</u>
Equity attributable to shareholders of Akumin Inc.	155,672,983	152,519,353
Non-controlling interests	5,376,781	4,544,149
Total shareholders' equity	<u>161,049,764</u>	<u>157,063,502</u>
Total liabilities and shareholders' equity	<u>710,236,485</u>	<u>683,000,517</u>

Approved by the Board of Directors

(signed) "Riadh Zine" Director

(signed) "Tom Davies" Director

The accompanying notes are an integral part of these condensed consolidated financial statements.

Akumin Inc.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

(expressed in US dollars unless otherwise stated)

	Three-month period ended September 30, 2020 \$	Three-month period ended September 30, 2019 \$	Nine-month period ended September 30, 2020 \$	Nine-month period ended September 30, 2019 \$
Revenue				
Service fees - net of allowances and discounts	66,586,937	68,223,340	190,381,224	168,588,127
Other revenue	537,503	650,592	2,706,419	1,822,142
	<u>67,124,440</u>	<u>68,873,932</u>	<u>193,087,643</u>	<u>170,410,269</u>
Operating expenses				
Cost of operations, excluding depreciation and amortization	48,853,449	50,845,807	146,542,793	130,916,682
Depreciation and amortization	5,251,401	4,700,153	15,409,599	11,359,218
Stock-based compensation	568,375	852,588	1,726,410	2,805,541
Operational financial instruments revaluation and other (gains) losses	3,673,348	475,682	(4,290,736)	657,264
Total operating expenses	<u>58,346,573</u>	<u>56,874,230</u>	<u>159,388,066</u>	<u>145,738,705</u>
Income from operations	<u>8,777,867</u>	<u>11,999,702</u>	<u>33,699,577</u>	<u>24,671,564</u>
Other income and expenses				
Interest expense	8,961,013	7,663,827	24,437,824	13,156,393
Other financial instruments revaluation and other (gains) losses	(285,554)	1,223,809	3,881,088	2,074,868
Settlement costs and other (recoveries)	1,611,747	(207,961)	2,491,412	(1,438,662)
Acquisition-related costs	173,621	443,944	473,843	2,993,629
Total other expenses (income)	<u>10,460,827</u>	<u>9,123,619</u>	<u>31,284,167</u>	<u>16,786,228</u>
Income (loss) before income taxes	<u>(1,682,960)</u>	<u>2,876,083</u>	<u>2,415,410</u>	<u>7,885,336</u>
Income tax provision (benefit)	<u>(985,609)</u>	<u>(397,519)</u>	<u>(966,144)</u>	<u>147,928</u>
Net income (loss) and comprehensive income (loss) for the period	<u>(697,351)</u>	<u>3,273,602</u>	<u>3,381,554</u>	<u>7,737,408</u>
Non-controlling interests	<u>852,770</u>	<u>590,517</u>	<u>1,954,334</u>	<u>1,583,893</u>
Net income (loss) attributable to common shareholders	<u>(1,550,121)</u>	<u>2,683,085</u>	<u>1,427,220</u>	<u>6,153,515</u>
Net income (loss) per share				
Basic and diluted	(0.02)	0.04	0.02	0.09

The accompanying notes are an integral part of these condensed consolidated financial statements.

(2)

Akumin Inc.

Condensed Consolidated Statements of Changes in Equity

(Unaudited)

(expressed in US dollars unless otherwise stated)

	Additional paid-in capital \$	Accumulated Deficit \$	Non-controlling interest \$	Total Shareholders' equity \$
Balance as at January 1, 2019	130,577,709	(15,789,745)	4,107,499	118,895,463
Net income and comprehensive income	-	6,153,515	1,583,893	7,737,408
Issuance of common shares – net of issuance costs				
Acquisition consideration	23,437,500	-	-	23,437,500
RSUs and Warrants exercised (note 10)	1,311,146	-	-	1,311,146
Stock-based compensation expense	2,805,541	-	-	2,805,541
Payment to non-controlling interests	-	-	(1,285,319)	(1,285,319)
Balance as at September 30, 2019	<u>158,131,896</u>	<u>(9,636,230)</u>	<u>4,406,073</u>	<u>152,901,739</u>
Balance as at December 31, 2019	158,881,120	(6,361,767)	4,544,149	157,063,502
Net income and comprehensive income	-	1,427,220	1,954,334	3,381,554
Stock-based compensation expense	1,726,410	-	-	1,726,410
Payment to non-controlling interests	-	-	(1,121,702)	(1,121,702)
Balance as at September 30, 2020	<u>160,607,530</u>	<u>(4,934,547)</u>	<u>5,376,781</u>	<u>161,049,764</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

Akumin Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(expressed in US dollars unless otherwise stated)

	Nine-month period ended September 30, 2020 \$	Nine-month period ended September 30, 2019 \$
Cash flows provided by (used in)		
Operating activities		
Net income for the period	3,381,554	7,737,408
Adjustments for:		
Depreciation and amortization	15,409,599	11,359,218
Stock-based compensation	1,726,410	2,805,541
Interest expense-accretion of debt and paid-in-kind interest	4,290,609	1,184,446
Deferred income tax expense (benefit)	(1,394,376)	(422,056)
Financial instruments revaluation and other (gains) losses	(409,648)	2,732,132
Changes in operating assets and liabilities		
Accounts receivable	(16,127,531)	(21,624,658)
Prepaid expenses, security deposits and other assets	1,005,359	(1,061,267)
Accounts payable and accrued liabilities	7,352,996	459,501
Operating lease liabilities and right-of-use assets	3,000,960	1,672,113
	<u>18,235,932</u>	<u>4,842,378</u>
Investing activities		
Purchase of property and equipment and intangible assets	(9,419,170)	(9,338,197)
Business acquisitions – net of cash acquired	(3,198,634)	(201,095,758)
Other investments	(463,789)	-
	<u>(13,081,593)</u>	<u>(210,433,955)</u>
Financing activities		
Loan proceeds	6,300,000	333,600,000
Loan repayments	(2,777,651)	(112,963,650)
Issuance costs – loans	(2,682,062)	(14,781,765)
Finance leases – principal payments	(905,296)	(639,259)
Subordinated notes	-	(1,500,000)
Common shares	-	1,311,146
Payment to non-controlling interests	(1,121,702)	(1,285,319)
	<u>(1,186,711)</u>	<u>203,741,153</u>
Increase (decrease) in cash during the period	3,967,628	(1,850,424)
Cash – Beginning of period	23,388,916	19,326,412
Cash – End of period	27,356,544	17,475,988
Supplementary information		
Interest expense paid	20,244,120	12,074,988
Income taxes paid	1,253,786	560,388

The accompanying notes are an integral part of these condensed consolidated financial statements.

(4)

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

1 Presentation of condensed consolidated financial statements and nature of operations

The operations of Akumin Inc. (Akumin or the Company) and its Subsidiaries (defined below) primarily consist of operating outpatient diagnostic imaging centres located in Delaware, Florida, Georgia, Illinois, Kansas, Pennsylvania and Texas. Substantially all of the centres operated by Akumin were obtained through acquisition. Related to its imaging centre operations, Akumin also operates a medical equipment business, SyncMed, LLC (SyncMed), which provides maintenance services to Akumin's imaging centres in Illinois, Kansas and Texas and a billing and revenue cycle management business, as a division of Akumin's wholly owned indirect subsidiary, Akumin Corp., which was previously operated by a subsidiary, Rev Flo Inc., which was merged into Akumin Corp. on December 31, 2018.

The services offered by the Company (through the Subsidiaries) include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, digital radiography (X-ray), fluoroscopy and other related procedures.

The Company has a diverse mix of payers, including private, managed care capitated and government payers.

The registered and Canadian head office of Akumin is located at 151 Bloor Street West, Suite 603, Toronto, Ontario, M5S 1S4. The United States head office is located at 8300 W. Sunrise Boulevard, Plantation, Florida, 33322. All operating activities are conducted through its wholly owned US subsidiary, Akumin Holdings Corp. and its wholly owned subsidiary, Akumin Corp. Akumin Corp. operates its business directly and through its key wholly owned direct and indirect subsidiaries, which include Akumin Florida Holdings, LLC, formerly known as Tri-State Imaging FL Holdings, LLC (FL Holdings), Akumin Imaging Texas, LLC, formerly known as Preferred Medical Imaging, LLC (PMI), SyncMed, Akumin FL, LLC (Akumin FL), Advanced Diagnostics Group, LLC (ADG), TIC Acquisition Holdings, LLC (TIC) and Akumin Health Illinois, LLC (Akumin IL) (collectively, the Subsidiaries), as well as through Delaware Open MRI Radiology Associates, LLC, Elite Imaging, LLC, Elite Radiology of Georgia, LLC, Jeanes Radiology Associates, LLC, Lebanon Diagnostic Imaging, LLC, Rittenhouse Imaging Center, LLC, Rose Radiology Centers, LLC and Wilkes-Barre Imaging, LLC (collectively, the Revenue Practices), all of which are located in the United States.

2 Basis of preparation

The Company adopted the accounting principles generally accepted in the United States of America (GAAP) as the basis of preparation for the 2020 annual financial statements effective for the fiscal year-ended December 31, 2020. Previously, the Company's financial statements were prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), for the period up to and including the 9-months ended September 30, 2020. On August 28, 2020, the Company filed a Form 40-F with the United States Securities and Exchange Commission pursuant to Section 12 of the Securities Exchange Act of 1934. This filing resulted in the Company becoming a "SEC Issuer" for purposes of National Instrument 51-102 -- Continuous Disclosure Obligations and as such the Company is entitled to prepare and report its financial statements in GAAP as opposed to IFRS.

These condensed interim consolidated financial statements for the three and nine month period ended September 30, 2020 have been prepared in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 270, Interim Reporting. The disclosures contained in these condensed interim consolidated financial statements in accordance with GAAP do not include all the requirements of GAAP for annual financial statements. The condensed interim consolidated financial

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2020. The condensed interim consolidated financial statements are based on accounting policies as described in the December 31, 2020 consolidated financial statements.

The condensed interim consolidated financial statements include all of the accounts of the Company, the Subsidiaries and the Revenue Practices. All intercompany transactions and balances have been eliminated on consolidation.

3 Variable interest entities

In accordance with the FASB's ASC Topic 810, *Consolidation*, a reporting entity with a variable interest in another entity is required to include the assets and liabilities and revenue and expenses of that separate entity (i.e., consolidate with the financial statements of the reporting entity) when the variable interest is determined to be a controlling financial interest. Under ASC 810, a reporting entity is considered to have a controlling financial interest in a variable interest entity (VIE) if (1) the reporting entity has the power to direct the activities of the VIE that most significantly impacts its economic performance and (2) the reporting entity has the obligation to absorb losses of the VIE that could be potentially significant to the VIE.

As a result of the financial relationship established between the Company and the Revenue Practices through respective management service agreements, the Revenue Practices individually qualify as VIEs as the Company, which provides them non-medical, technical and administrative services, has the power to direct their respective activities and the obligation to absorb their gains and losses. As a result, the Company is considered the primary beneficiary of the Revenue Practices, and accordingly, the assets and liabilities and revenue and expenses of the Revenue Practices are included in these condensed consolidated financial statements. The following information excludes any intercompany transactions and costs allocated by the Company to the Revenue Practices. The Revenue Practices' assets and liabilities included in the Company's consolidated balance sheets as at September 30, 2020 were \$64.6 million (2019 – \$58.7 million) and \$2.4 million (2019 – \$nil), respectively. The assets of the Revenue Practices can only be used to settle their obligations. During the nine month period ended September 30, 2020, the Revenue Practices' net revenue was \$110.4 million (2019 – \$107.0 million) and the net contribution to the Company's cash flow from operations was \$98.6 million (2019 – \$77.0 million).

The Company has a variable interest in a single purpose entity in Texas which operates an imaging center. The Company also has a variable interest in certain operations of an imaging center of another Texas entity. In both cases, the Company is not a primary beneficiary of the variable interest since it does not have any equity ownership in these entities nor does it have the power to direct the activities of either of these entities that most significantly impact the entities' economic performance. Rather, in both cases, the Company is entitled to a management fee based upon written agreements in exchange for certain agreed upon management services. The assets and liabilities and revenue and expenses of these entities are not included in the consolidated financial statements of the Company.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

4 Business combinations

- i) On January 1, 2020, the Company acquired, through a subsidiary, a single outpatient diagnostic imaging centre in Coral Springs, Florida, for cash consideration of approximately \$2.1 million (Coral Springs Acquisition). In accordance with the transaction agreement, \$100,000 of this purchase price (Holdback Fund) was withheld as security for indemnity obligations and was released to the seller during June 2020. This asset acquisition was considered a business combination. The Company has made a preliminary fair value determination of the acquired assets and assumed liabilities as follows:

	\$
Assets acquired	
Current assets	
Prepaid expenses	32,961
Non-current assets	
Security deposits	368,601
Property and equipment	412,400
Operating lease right-of-use assets	<u>2,427,618</u>
	<u>3,241,580</u>
Liabilities assumed	
Non-current liabilities	
Operating lease liabilities (right-of-use)	<u>2,427,618</u>
Net assets acquired	813,962
Goodwill	<u>1,274,764</u>
Purchase price	<u>2,088,726</u>

This acquisition was an opportunity for the Company to increase its economies of scale across Florida. The goodwill assessed on acquisition, expected to be deductible for income tax purposes, reflects the Company's expectation of future benefits from the acquired business and workforce, and potential synergies from cost savings. The results of operations of this acquisition have been included in the Company's condensed consolidated statements of operations and comprehensive income (loss) from the acquisition date. Since the acquisition date, this acquisition contributed revenue of approximately \$2.9 million and income before tax of approximately \$0.5 million to the Company's consolidated results for the nine months ended September 30, 2020.

- ii) On January 1, 2020, the Company acquired, through a subsidiary, a single outpatient diagnostic imaging centre in Crystal Lake, Illinois, for cash consideration of approximately \$1.2 million (Crystal Lake Acquisition). In accordance with the transaction agreement, \$60,000 of this purchase price (Holdback Fund) was withheld as security for indemnity obligations and was released to the seller during June 2020. This asset acquisition was considered a business combination. The Company has made a preliminary fair value determination of the acquired assets and assumed liabilities as follows:

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

	\$
Assets acquired	
Non-current assets	
Security deposits	5,799
Property and equipment	820,000
Operating lease right-of-use assets	554,830
	<u>1,380,629</u>
Liabilities assumed	
Non-current liabilities	
Operating lease liabilities (right-of-use)	554,830
	<u>554,830</u>
Net assets acquired	825,799
Goodwill	400,000
	<u>1,225,799</u>
Purchase price	<u>1,225,799</u>

This acquisition was an opportunity for the Company to increase its presence in Illinois. The goodwill assessed on acquisition, expected to be deductible for income tax purposes, reflects the Company's expectation of future benefits from the acquired business and workforce, and potential synergies from cost savings. The results of operations of this acquisition have been included in the Company's condensed consolidated statements of operations and comprehensive income (loss) from the acquisition date. Since the acquisition date, this acquisition contributed revenue of approximately \$0.7 million and income before tax of approximately \$0.1 million to the Company's consolidated results for the nine months ended September 30, 2020.

- iii) On August 16, 2019, the Company acquired, through a subsidiary, five outpatient diagnostic imaging centres in El Paso, Texas, for cash consideration of \$11 million (El Paso Acquisition). The cash purchase price was decreased during 2020 by approximately \$16 thousand due to working capital adjustments in accordance with the purchase agreement. The Company has made a fair value determination of the acquired assets and assumed liabilities as at the date of acquisition, as follows. The intangible assets consist of the trade name and covenants not to compete.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

	2020 \$	2019 \$
Assets acquired		
Current assets		
Accounts receivable	1,275,726	1,275,726
Prepaid expenses	19,789	19,789
	<u>1,295,515</u>	<u>1,295,515</u>
Non-current assets		
Property and equipment	3,922,481	3,922,481
Operating lease right-of-use assets	3,683,989	3,683,989
Intangible assets	720,000	720,000
	<u>9,621,985</u>	<u>9,621,985</u>
Liabilities assumed		
Current liabilities		
Accounts payable and accrued liabilities	1,174,040	1,024,631
Non-current liabilities		
Operating lease liabilities (right-of-use)	3,683,989	3,683,989
	<u>4,858,029</u>	<u>4,708,620</u>
Net assets acquired	4,763,956	4,913,365
Goodwill	6,220,153	6,086,635
	<u>10,984,109</u>	<u>11,000,000</u>
Purchase price		

- iv) On October 4, 2019, the Company acquired, through a subsidiary, three outpatient diagnostic imaging centres in West Palm Beach, Florida, for cash consideration of approximately \$18 million (West Palm Beach Acquisition). The cash purchase price was decreased during 2020 by approximately \$0.1 million due to working capital adjustments in accordance with the purchase agreement. The Company has made a fair value determination of the acquired assets and assumed liabilities as at the date of acquisition, as follows. The intangible assets consist of the trade name and covenants not to compete.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

	2020 \$	2019 \$
Assets acquired		
Current assets		
Accounts receivable	2,085,491	2,085,491
Prepaid expenses	90,454	90,454
	<u>2,175,945</u>	<u>2,175,945</u>
Non-current assets		
Security deposits	9,000	9,000
Property and equipment	2,432,234	2,432,234
Operating lease right-of-use assets	13,625,521	13,625,521
Intangible assets	1,080,000	1,080,000
	<u>19,322,700</u>	<u>19,322,700</u>
Liabilities assumed		
Current liabilities		
Accounts payable and accrued liabilities	1,404,268	1,311,471
Non-current liabilities		
Finance leases	587,434	587,434
Operating lease liabilities (right-of-use)	13,625,521	13,625,521
	<u>15,617,223</u>	<u>15,524,426</u>
Net assets acquired	3,705,477	3,798,274
Goodwill	14,064,109	14,071,312
Purchase price	<u>17,769,586</u>	<u>17,869,586</u>

5 Property and equipment

	September 30, 2020 \$	December 31, 2019 \$
Medical equipment	83,572,729	75,665,771
Equipment under finance leases	20,629,947	14,971,916
Leasehold improvements	18,192,624	17,393,839
Furniture and fixtures	1,313,563	1,088,236
Office equipment	211,032	214,612
Computer equipment	240,919	194,770
	<u>124,160,814</u>	<u>109,529,144</u>
Total property and equipment – cost	124,160,814	109,529,144
Less: Accumulated depreciation	(46,188,552)	(33,590,554)
	<u>77,972,262</u>	<u>75,938,590</u>
Total property and equipment – net	<u>77,972,262</u>	<u>75,938,590</u>

As at September 30, 2020, the equipment under finance leases had a net book value of \$12,959,512 (2019 - \$9,404,765). Depreciation expense for the three and nine months ended September 30, 2020 was \$4,591,715 and \$13,389,923, respectively (2019 – \$3,750,222 and \$9,902,454). As part of ongoing operations, during the

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

three and nine months ended September 30, 2020, the Company had net disposals of \$522,819 and \$1,303,724, respectively (2019 – \$91,549 and \$189,711). The loss on these disposals is included in the condensed consolidated statements of operations and comprehensive income (loss) in the expense category “financial instruments revaluation and other gains (losses)”.

6 Earn-out liability (ADG Acquisition)

	September 30, 2020 \$	December 31, 2019 \$
ADG Acquisition – earn-out	9,377,106	14,834,067
Less: Current portion of ADG Acquisition – earn-out	<u>(9,377,106)</u>	<u>(7,529,962)</u>
Non-current portion of ADG Acquisition – earn-out	<u>-</u>	<u>7,304,105</u>

A portion of the purchase price payable in respect of the ADG Acquisitions in 2019, specifically for SFL Radiology Holdings, LLC (Georgia business), was subject to an earn-out (the ADG Acquisition – earn-out liability) based on its annualized revenues earned in the first two quarters of 2020 less certain costs including certain operating expenses, capital expenditures and incremental working capital. In accordance with the purchase agreement, 50% of this liability is expected to be settled in the latter half of 2020 and the balance in the first half of 2021.

The value of the ADG Acquisition – earn-out liability was estimated by management using a probability weighted valuation technique related to information including revenue and operating expenses; changes in the fair value of this liability are recognized in the condensed consolidated statements of operations and comprehensive income (loss). Management estimated the fair value of the ADG Acquisition – earn-out liability as at May 31, 2019 at approximately \$14.7 million based on a discount rate of approximately 7% and management’s estimated probability weighted range of the ADG Acquisition – earn-out liability (it is considered a Level 3 liability as described in note 13; this liability was subsequently settled as noted below). An increase in the discount rate by 1.0% point decreased the value of this liability by about \$0.2 million and vice versa. Subsequently, the ADG Acquisition – earn-out liability estimate was revalued at approximately \$14.8 million as at December 31, 2019, at approximately \$8.3 million as at March 31, 2020 and at approximately \$6.2 million as at June 30, 2020 and the respective changes in fair value were recognized in financial instruments revaluation in the related condensed consolidated statements of operations and comprehensive income (loss). As of September 30, 2020, this liability was revalued at approximately \$9.4 million based on a settlement reached pursuant to the terms of the purchase agreement with the representatives of the sellers of the Company’s Georgia business and the change in fair value was recognized in financial instruments revaluation in the related condensed consolidated statements of operations and comprehensive income (loss). As discussed in note 19, 50% of this liability was paid in November 2020 and the balance is to be paid in May 2021 pursuant to the process outlined in the related purchase agreement, a copy of which is available under the Company’s profile on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

7 Lease liabilities

Finance

The information pertaining to finance lease liabilities on the consolidated balance sheet is as follows:

	September 30, 2020 \$	December 31, 2019 \$
Finance lease liabilities	13,453,771	8,415,404
Less: Current portion of finance lease liabilities	(2,907,779)	(1,789,995)
Non-current portion of finance lease liabilities	<u>10,545,992</u>	<u>6,625,409</u>

The components of finance lease cost recognized in the consolidated statement of operations and comprehensive income (loss) are as follows:

	Three-month period ended September 30, 2020 \$	Three-month period ended September 30, 2019 \$	Nine-month period ended September 30, 2020 \$	Nine-month period ended September 30, 2019 \$
Amortization expense for equipment under finance leases	818,209	414,035	2,307,222	1,103,956
Interest expense on finance lease liabilities	164,947	73,658	461,400	189,940
Finance lease cost	<u>983,156</u>	<u>487,693</u>	<u>2,768,622</u>	<u>1,293,896</u>

Undiscounted cash flows for finance leases recorded in the consolidated balance sheets were as follows at September 30, 2020.

	\$
October 1 to December 31, 2020	871,341
2021	3,448,743
2022	3,254,284
2023	2,845,390
2024	2,199,966
Thereafter	<u>2,451,161</u>
Total minimum lease payments	15,070,885
Less: Amount of lease payments representing interest	<u>(1,617,114)</u>
Present value of future minimum lease payments	13,453,771
Less: Current portion of finance lease liabilities	<u>(2,907,779)</u>
Non-current finance lease liabilities	<u>10,545,992</u>

The lease term and discount rates are as follows:

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

	September 30, 2020	December 31, 2019
Weighted average remaining lease term-finance leases (years)	4.8	4.8
Weighted average discount rate-finance leases	4.8%	5.1%

Supplemental cash flow information related to finance leases is as follows:

	Nine-month period ended September 30, 2020 \$	Nine-month period ended September 30, 2019 \$
Operating cash flows from finance leases	461,400	189,940
Financing cash flows from finance leases	905,296	639,259
Right-of-use assets obtained in exchange for finance lease obligations	5,991,365	2,596,167

Operating

The information pertaining to operating lease liabilities on the consolidated balance sheet is as follows:

	September 30, 2020 \$	December 31, 2019 \$
Operating lease liabilities	137,416,885	129,049,990
Less: Current portion of operating lease liabilities	(9,470,609)	(9,276,298)
Non-current portion of operating lease liabilities	<u>127,946,276</u>	<u>119,773,692</u>

The components of operating lease cost recognized in the consolidated statement of operations and comprehensive income (loss) are as follows:

	Three-month period ended September 30, 2020 \$	Three-month period ended September 30, 2019 \$	Nine-month period ended September 30, 2020 \$	Nine-month period ended September 30, 2019 \$
Operating lease cost	5,161,282	4,705,229	15,508,540	12,880,400
Variable lease cost	573,129	936,494	3,561,135	2,459,198
Short-term lease cost	83,719	75,162	209,426	96,083
Total operating lease cost	<u>5,818,130</u>	<u>5,716,885</u>	<u>19,279,101</u>	<u>15,435,681</u>

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

Undiscounted cash flows for operating leases recorded in the consolidated balance sheets were as follows at September 30, 2020.

	\$
October 1 to December 31, 2020	4,739,268
2021	18,769,664
2022	17,992,289
2023	17,169,711
2024	16,446,674
Thereafter	<u>160,684,575</u>
Total minimum lease payments	235,802,181
Less: Amount of lease payments representing interest	<u>(98,385,296)</u>
Present value of future minimum lease payments	137,416,885
Less: Current portion of operating lease liabilities	<u>(9,470,609)</u>
Non-current operating lease liabilities	<u>127,946,276</u>

The lease term and discount rates are as follows:

	September 30, 2020	December 31, 2019
Weighted average remaining lease term-operating leases (years)	13.1	14.1
Weighted average discount rate-operating leases	7.5%	7.1%

Supplemental cash flow information related to operating leases is as follows:

	Nine-month period ended September 30, 2020 \$	Nine-month period ended September 30, 2019 \$
Operating cash flows from operating leases	12,507,580	11,208,287
Right-of-use assets obtained in exchange for operating lease obligations	16,099,338	133,482,766

8 Senior loans payable

The Amended May 2019 Loans and Wesley Chapel Loan are collectively referred to as the Senior Loans.

The minimum annual principal payments with respect to the Senior Loans (face value) as at September 30, 2020 are as follows:

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

	\$
October 1, 2020 to December 31, 2020	928,301
2021	5,045,698
2022	6,881,454
2023	7,246,356
2024	<u>341,864,398</u>
	<u>361,966,207</u>

Amended May 2019 Loans

On June 2, 2020, the Company entered into an amendment to its senior credit agreement which amended the credit agreement signed effective May 31, 2019 (such amended credit agreement, the Amended May 2019 Credit Agreement). Under the terms of the Amended May 2019 Credit Agreement, the Company received in May 2019 a term loan A and term loan B (Term Loan A, Term Loan B and collectively, Term Loans) of \$66,000,000 and \$266,000,000, respectively (face value) and a revolving credit facility of \$50,000,000, which was increased to \$69,000,000 on June 2, 2020 (the Revolving Facility, and together with the Term Loans, the Amended May 2019 Loans). In addition, among other things, the amendment adjusted Akumin's leverage and fixed charge ratios for the four quarters ended March 31, 2021, providing the Company with greater flexibility in its financial ratio covenants. Sixteen million dollars of the Term Loan A was subject to a delayed draw, which was drawn by the Company in October 2019 to partly finance the West Palm Beach Acquisition. The term of the Amended May 2019 Loans is five years from May 31, 2019. The Amended May 2019 Loans can be increased by an additional \$100,000,000 subject to certain conditions. The proceeds of the Term Loans were used during 2019 to settle the Syndicated Loans for \$112,482,181, the principal outstanding under Subordinated Note and related accrued and unpaid interest for \$1,596,250, partly finance the ADG Acquisitions and Deltona Acquisition in May 2019 and pay related debt issuance costs. On May 31, 2019, management determined the fair value of the Amended May 2019 Loans to be their face value of \$319,300,000 net of debt issuance costs of approximately \$14.8 million and a debt modification accounting adjustment of approximately \$1.0 million related to the settlement of the Syndicated Loans. The fair value of the Amended May 2019 Loans was determined based on management's estimation of assumptions that market participants would use in pricing similar liabilities (it is considered a Level 3 liability as described in note 13). As at December 31, 2019, the Amended May 2019 Loans had a balance of approximately, \$338.5 million. In June 2020, the amendment costs related to the Amended May 2019 Credit Agreement were netted against the balance of the Amended May 2019 Loans. The above-noted amendment to the senior credit agreement in June 2020 was considered debt modification for accounting purposes. As at September 30, 2020, the Amended May 2019 Loans had an amortized cost balance of approximately, \$343.9 million. As discussed in note 19, the Amended May 2019 Loans and related accrued and unpaid interest and costs were settled completely on November 2, 2020 using proceeds of the 2025 Senior Notes.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

	September 30, 2020	December 31, 2019
	\$	\$
Term Loan A and Revolving Facility	93,629,000	87,824,000
Term Loan B	250,310,809	250,710,995
Less: Current portion	<u>(3,980,000)</u>	<u>(3,320,000)</u>
	<u>339,959,809</u>	<u>335,214,995</u>

Subject to the provisions described below, the minimum annual principal payments with respect to the Amended May 2019 Loans (face value) are as follows.

a) Term Loan A and Revolving Facility

	\$
October 1, 2020 to December 31, 2020	165,000
2021	1,980,000
2022	3,795,000
2023	4,290,000
2024	<u>83,399,000</u>
	<u>93,629,000</u>

b) Term Loan B

	\$
October 1, 2020 to December 31, 2020	665,000
2021	2,660,000
2022	2,660,000
2023	2,660,000
2024	<u>258,465,398</u>
	<u>267,110,398</u>

Effective November 14, 2018, the Company entered into a derivative financial instrument contract with a financial institution in order to mitigate interest rate risk under the variable interest rate Syndicated Loans (which were settled in 2019). The derivative financial instrument is an interest rate cap rate of 3.75% (LIBOR) per annum on a notional amount of 50% of the face value of the Syndicated Term Loan (\$50,000,000 as at November 14, 2018). The termination date of this arrangement is August 31, 2021. The cost of this derivative financial instrument was \$155,000. The Company has not designated this interest rate cap agreement as a cash flow hedge for accounting purposes. The fair value of this derivative as determined by the financial institution as at September 30, 2020 represented an asset to the Company of \$8 (2019 - \$597). As discussed in note 19, this derivative financial instrument was terminated and settled completely on November 2, 2020.

In addition, effective July 31, 2019, the Company entered into a derivative financial instrument, an interest rate collar contract (further amended in November 2019 and February 2020), with a financial institution in order to mitigate interest rate risk under the variable interest rate Term Loans. This derivative financial instrument has an underlying notional amount of 100% of the face value of Term Loan B (\$266,000,000 as at July 31, 2019) and a

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

termination date of July 31, 2022 with (i) a cap rate of 3.00% (LIBOR) per annum, and (ii) a floor rate of 1.1475% (LIBOR) per annum. There was no upfront cost of this derivative financial instrument. The Company has not designated this interest rate cap agreement as a cash flow hedge for accounting purposes. The fair value of this derivative as determined by the Company as at September 30, 2020 represented a liability to the Company of \$4,905,871 (2019 - \$951,702). As discussed in note 19, this derivative financial instrument was terminated and settled completely on November 2, 2020.

Changes in the fair value of these derivatives are recognized in the condensed consolidated statements of operations and comprehensive income (loss) in the line "Financial instruments revaluation and other (gains) losses". During the nine-month period ended September 30, 2020, the Company incurred interest expense of \$1,082,767 (2019 - \$nil) with respect to the derivative financial instrument that was entered into in July 2019. The interest expense was paid on a monthly basis.

The Amended May 2019 Credit Agreement provides for the following (capitalized terms used below in this note and not defined elsewhere in these notes have the respective meanings given to them in the Amended May 2019 Credit Agreement):

- Interest

The interest rates payable on the Amended May 2019 Loans are as follows: (i) each Eurodollar Rate Loan shall bear interest on the outstanding principal amount at one-month LIBOR plus Applicable Rate; and (ii) each Base Rate Loan shall bear interest on the outstanding principal amount at the Base Rate (the highest of (a) the Federal Funds Rate plus 0.5%, (b) the prime rate and (c) Eurodollar Rate plus 1.0%) plus Applicable Rate. As part of the amendments on June 2, 2020, an additional paid-in-kind interest accrues on the outstanding Term B Loans from time to time, which interest rate shall be (i) 2.00% per annum from June 2, 2020 to March 31, 2021, and (ii) thereafter the applicable percentage per annum will be determined by reference to the leverage ratio thresholds in the Amended May 2019 Credit Agreement. All advances under the Amended May 2019 Loans are currently classified as Eurodollar Rate Loans. The annualized effective interest rate under the Amended May 2019 Credit Agreement as at September 30, 2020 was approximately 7.6% per annum (September 30, 2019 – 8.1%). With respect to interest rate sensitivity as at September 30, 2020, a 1% increase in variable interest rates would have increased interest expense for the nine-month period ended September 30, 2020 by approximately \$0.4 million (2019 – \$1.1 million).

- Payments

The minimum principal payment schedule for the Amended May 2019 Loans is noted herein.

- Termination

The termination date of the Amended May 2019 Loans is the earliest of (i) May 31, 2024 and (ii) the date on which the obligations become due and payable pursuant to the Amended May 2019 Credit Agreement.

- Restrictive covenants

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

In addition to certain covenants, the Amended May 2019 Credit Agreement places limits on the Company's ability to declare dividends or redeem or repurchase capital stock (including options or warrants), prepay, redeem or purchase debt, incur liens and engage in sale-leaseback transactions, make loans and investments, incur additional indebtedness, amend or otherwise alter debt and other material agreements, engage in mergers, acquisitions, capital expenditures and asset sales, enter into transactions with affiliates and alter the business the Company and the Subsidiaries currently conduct.

- Financial covenants

The Amended May 2019 Credit Agreement contains financial covenants including certain leverage ratios and a limit on annual capital expenditures.

The Company is in compliance with the financial covenants and has no events of default under the Amended May 2019 Credit Agreement as at September 30, 2020.

- Events of default

In addition to the above noted financial covenants, events of default under the Amended May 2019 Credit Agreement include, among others, failure to pay principal of or interest on any Amended May 2019 Loans when due, failure to pay any fee or other amount due within two days after the same comes due, failure of any loan party to comply with any covenants or agreements in the loan documents (subject to applicable grace periods and/or notice requirements), a representation or warranty contained in the loan documents is incorrect or misleading when made, events of bankruptcy and a change of control. The occurrence of an event of default would permit the lenders under the Amended May 2019 Credit Agreement to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

- Security

The Company has, subject to limited exceptions, granted general security over all assets of the Company and the Subsidiaries in connection with the Amended May 2019 Loans.

Wesley Chapel Loan

As part of the Rose Acquisition in 2018, the Company, through a subsidiary, assumed a senior secured loan (Wesley Chapel Loan) of \$2,000,000 (face value) as of August 15, 2018 to finance the purchase of equipment and related installation at a clinic location around Tampa Bay, Florida. It has an annual interest rate of 5.0%, matures on August 15, 2023 and has monthly repayments of \$37,742. The Wesley Chapel Loan was recognized at fair value of \$1,908,456 on August 15, 2018 using an effective interest rate. The fair value was determined based on management's estimation of assumptions that market participants would use in pricing similar liabilities (it is considered a Level 3 liability as described in note 13). As at September 30, 2020, the Wesley Chapel Loan had an amortized cost balance of approximately, \$1.2 million.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

	September 30, 2020 \$	December 31, 2019 \$
Wesley Chapel Loan	1,173,408	1,447,327
Less: Current portion	(400,668)	(385,952)
	<u>772,740</u>	<u>1,061,375</u>

Subject to the provisions described below, the minimum annual principal payments with respect to the Wesley Chapel Loan (face value) are as follows:

	\$
October 1, 2020 to March 31, 2020	98,301
2021	405,698
2022	426,454
2023	296,356
	<u>1,226,809</u>

The Wesley Chapel Loan provides for the following terms:

- Interest

5.0%.

- Payments

Monthly payments (principal and interest) of \$37,742. The minimum principal payment schedule for the Wesley Chapel Loan is noted herein.

- Termination

August 15, 2023.

- Restrictive covenants

In addition to certain covenants, the Wesley Chapel Loan limits the Company's ability to dispose of the assets of Akumin Corp., which is the guarantor to the Wesley Chapel Loan.

- Financial covenants

None.

- Events of default

Events of default under the Wesley Chapel Loan include, among others, failure to repay the Wesley Chapel Loan in full at maturity, or to pay any other sum due hereunder within ten days of the date when the payment is due, events of insolvency or disposition of all or substantially all of the assets related to the

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

Rose Acquisition. The occurrence of an event of default would permit the lender to declare all amounts borrowed, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

The Company has no events of default under the Wesley Chapel Loan as at September 30, 2020.

- Security

The Company has granted first security interest to the lender over the equipment and leasehold improvements acquired using the proceeds of the Wesley Chapel Loan.

9 Subordinated notes payable – earn-out

	September 30, 2020 \$	December 31, 2019 \$
Subordinated note – earn-out	200,000	184,485

As part of the Tampa Acquisition, Akumin FL entered into a subordinated 6% note and security agreement with the seller's secured lender on May 11, 2018 (the Subordinated Note and Subordinated Note Lender, respectively) with a face value of \$1,500,000 and a term of four years. The Subordinated Note was recognized at fair value of \$1,490,932 on May 11, 2018 using an effective interest rate. The fair value was determined based on management's estimation of assumptions that market participants would use in pricing similar liabilities (it is considered a Level 3 liability as described in note 13; this liability was subsequently settled as noted below).

In accordance with the terms of the Subordinated Note, the Company used part of the proceeds of the Term Loans to settle the principal outstanding under the Subordinated Note on May 31, 2019, together with accrued and unpaid interest, for \$1,596,250 (face value of \$1,500,000 and accrued interest of \$96,250). The Company also recorded a fair value loss of \$6,830 on the extinguishment of the Subordinated Note, which was reflected in the 2019 consolidated statements of operations and comprehensive income (loss).

According to the Subordinated Note, the Company was subject to an earn-out liability (Subordinated Note – Earn-out) of up to \$4.0 million during the three-calendar year period beginning on January 1, 2019 and ending on December 31, 2021 (the Subordinated Note – Earn-out Period), subject to the satisfaction of certain revenue-based milestones, as follows:

- a) The Subordinated Note – Earn-out for any given calendar year during the Subordinated Note – Earn-out Period shall be equal to 50% of any positive difference calculated by subtracting the Base Revenue (\$16,000,000) for such calendar year from the Subordinated Note – Earn-out Revenue (defined below) for such calendar year.
- b) The Subordinated Note – Earn-out Revenue for any calendar year during the Subordinated Note – Earn-out Period shall be the gross revenue generated by the centres related to the Tampa Acquisition during such calendar year.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

- c) If Subordinated Note – Earn-out Revenue for any calendar year of the Subordinated Note – Earn-out Period is less than or equal to \$16,000,000, no Subordinated Note – Earn-out shall be payable for such calendar year.
- d) The maximum aggregate amount of the Subordinated Note – Earn-out that may be earned over the Subordinated Note – Earn-out Period is \$4,000,000.

The value of Subordinated Note – Earn-out has been estimated by management using a probability-weighted valuation technique; changes in the fair value of this liability are recognized in the condensed consolidated statements of operations and comprehensive income (loss). Management estimated the fair value of Subordinated Note – Earn-out as at May 11, 2018 of \$160,790 based on a discount rate of 8.75% and management's estimated probability-weighted range of Subordinated Note – Earn-out Revenue during the Subordinated Note – Earn-out Period (it is considered a Level 3 liability as described in note 13; this liability was subsequently settled as noted below). The Subordinated Note – Earn-out was revalued at \$200,000 as at September 30, 2020 and the change in fair value was recognized in financial instruments revaluation in the condensed consolidated statements of operations and comprehensive income (loss). As discussed in note 19, the Company entered into a settlement with the holders of the Subordinated Note – Earn-out to fully settle and terminate the Subordinated Note – Earn-out for \$200,000 on October 23, 2020.

Payments and termination

Under the Subordinated Note agreement, prior to May 11, 2022 (the Maturity Date), the Company may repay, without penalty, all or any portion of the Subordinated Note – Earn-out, and accrued but unpaid interest.

Restrictive covenants

The Subordinated Note agreement places certain limits on Akumin FL's ability to declare dividends or other distributions, incur liens or indebtedness, make investments, undertake mergers or reorganizations or dispose of assets outside the ordinary course of business.

Financial covenants

None.

Events of default

Events of default under the Subordinated Note agreement include failure to pay any Subordinated Note – Earn-out, once earned, together with interest when due, defaults in complying with terms of the Subordinated Note agreement, and the occurrence of bankruptcy events relating to Akumin FL. The occurrence of an event of default would permit the Subordinated Note Lender to declare any Subordinated Note – Earn-out, once earned, together with accrued interest and fees, to be immediately due and payable and to exercise other default remedies.

Security

The Company has granted a security interest over all assets of Akumin FL as security for its obligations under the Subordinated Note. The Subordinated Note – Earn-out is subordinate to the intercompany loan from the Company to Akumin FL.

The Company is in compliance with the terms of the Subordinated Note agreement as at September 30, 2020.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

10 Capital stock and warrants

The authorized share capital of the Company consists of an unlimited number of voting common shares, with no par value.

	Common shares		Warrants		RSUs		Total	
	Number	Amount \$	Number	Amount \$	Number	Amount \$	Number	Amount \$
January 1, 2019	62,371,275	123,746,423	1,249,512	1,742,910	1,120,656	2,671,147	64,741,443	128,160,480
Issuance (i)	6,250,000	23,437,500	-	-	-	1,559,418	6,250,000	24,996,918
RSUs and warrants exercised	1,219,653	4,813,632	(436,497)	(569,733)	(783,156)	(2,932,753)	-	1,311,146
Warrants expired	-	-	(288,015)	(438,798)	-	-	(288,015)	(438,798)
December 31, 2019	69,840,928	151,997,555	525,000	734,379	337,500	1,297,812	70,703,428	154,029,746
Issuance (i)	-	-	-	-	-	14,138	-	14,138
RSUs and warrants exercised	337,500	1,311,950	-	-	(337,500)	(1,311,950)	-	-
Warrants expired	-	-	(525,000)	(734,379)	-	-	(525,000)	(734,379)
September 30, 2020	70,178,428	153,309,505	-	-	-	-	70,178,428	153,309,505

(i) RSU issuance amount includes stock-based compensation and costs related to RSUs during the period of the condensed consolidated financial statements.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

During the nine months ended September 30, 2019, the following equity issuances or exercise or expiry of equity related instruments occurred at the Company.

- a) During the three months ended March 31, 2019, the following equity issuances or exercise or expiry of equity related instruments occurred at the Company:
 - i) During March 2017, the Company issued 300,825 warrants to purchase common shares on a 1:1 basis at an exercise price of \$2.30 per common share. These warrants were scheduled to expire on March 10 and 17, 2019. During the three months ended September 30, 2018, 120,330 of these warrants were exercised into common shares. The remaining 180,495 warrants were exercised into common shares prior to expiry during the three months ended March 31, 2019.
 - ii) The Board had granted 315,000 RSUs to certain employees of the Company between January 1 and March 12, 2018. Fifty percent of these RSUs vested between January 1 and March 12, 2019 in accordance with the terms of the RSU Plan and 25,000 of these vested RSUs were settled for common shares prior to March 31, 2019.
- b) During the three months ended June 30, 2019, the following equity issuances or exercise or expiry of equity related instruments occurred at the Company:
 - i) The Company issued approximately \$23 million in equity (6,250,000 common shares at \$3.75 per share, the closing price as of May 31, 2019) to certain sellers in connection with the ADG Acquisitions.
 - ii) During August 2017, the Company issued 512,004 warrants to purchase common shares on a 1:1 basis at an exercise price of \$3.50 per common share. The expiry date for these warrants was August 8, 2019. During the three months ended June 30, 2019, 256,002 of these warrants were exercised into common shares.
 - iii) The Board had granted 315,000 RSUs to certain employees of the Company between January 1 and March 12, 2018. Fifty percent of these RSUs vested between January 1 and March 12, 2019 in accordance with the terms of the RSU Plan and 25,000 of these vested RSUs were settled for common shares prior to March 31, 2019. The remaining 132,500 of these vested RSUs were settled for common shares prior to June 30, 2019.
- c) During the three months ended September 30, 2019, the following equity issuances or exercise or expiry of equity related instruments occurred at the Company:
 - i) During August 2017, the Company issued 512,004 warrants to purchase common shares on a 1:1 basis at an exercise price of \$3.50 per common share. The expiry date for these warrants was August 8, 2019. During the three months ended June 30, 2019, 256,002 of these warrants were exercised into common shares. The remaining 256,002 of these warrants were not exercised into common shares and expired on August 8, 2019.

During the nine months ended September 30, 2020, the following equity issuances or exercise or expiry of equity related instruments occurred at the Company.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

- a) During the three months ended March 31, 2020, the following equity issuances or exercise or expiry of equity related instruments occurred at the Company:
 - ii) As at December 31, 2019, the Company had 337,500 RSUs outstanding. All of these RSUs vested between January 1, 2020 and March 12, 2020. 285,000 of these RSUs were settled for common shares on March 12, 2020 in accordance with the terms of the RSU Plan. As at March 31, 2020, the Company had 52,500 RSUs outstanding.
- b) During the three months ended June 30, 2020, the following equity issuances or exercise or expiry of equity related instruments occurred at the Company:
 - i) As at March 31, 2020, the Company had 52,500 RSUs outstanding. All of these RSUs vested between January 1, 2020 and March 12, 2020 and they were settled for common shares in accordance with the terms of the RSU Plan as follows. 10,000 of these RSUs were settled for common shares in April 2020 and the remaining RSUs were settled for common shares in June 2020. As at June 30, 2020 and September 30, 2020, the Company had no RSUs outstanding.
 - iii) During May 2018, the Company had issued 525,000 warrants to purchase common shares on a 1:1 basis at an exercise price of \$4.00 per common share. These warrants were not exercised into common shares and expired on May 2, 2020.
- c) During the three months ended September 30, 2020, there were no equity issuances or exercise or expiry of equity related instruments at the Company.

The stock-based compensation related to RSUs, recognized in the condensed consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2020 was \$nil and \$14,138, respectively (2019 – \$441,532 and \$1,352,870).

The stock-based compensation related to stock options, recognized in the condensed consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2020, was \$568,375 and \$1,712,272, respectively (2019 – \$411,056 and \$1,452,671).

11 Commitments and contingencies

The Company is party to various legal proceedings, claims, and regulatory, tax or government inquiries and investigations that arise in the ordinary course of business. With respect to these matters, the management evaluates the developments on a regular basis and accrues a liability when it believes a loss is probable and the amount can be reasonably estimated. We believe that the amount or any estimable range of reasonably possible or probable loss will not, either individually or in the aggregate, have a material adverse effect on our business and condensed consolidated financial statements. However, the outcome of these matters is inherently uncertain. Therefore, if one or more of these matters were resolved against the Company for amounts in excess of management's expectations, our results of operations and financial condition, including in a particular reporting period in which any such outcome becomes probable and estimable, could be materially adversely affected.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

Management believes a loss is probable in connection with the settlement of a government investigation that relates predominantly to historical reimbursements paid under federal healthcare programs to subsidiaries or the Revenue Practices. Management estimates the amount of the loss to be around \$0.7 million to \$0.9 million and that it would be paid prior to December 31, 2020. As a result, at September 30, 2020, a provision for this matter is included in accounts payable and accrued liabilities.

Commencing during Q1 2020 and continuing through the present and beyond, a pandemic relating to the novel coronavirus known as COVID-19 occurred causing significant financial market disruption and social dislocation. The pandemic is dynamic with various cities, counties, states and countries around the world responding or having responded in different ways to address and contain the outbreak, including the declaration of a global pandemic by the World Health Organization, a National State of Emergency in the United States and state and local executive orders and ordinances forcing the closure of non essential businesses and persons not employed in or using essential services to “stay at home” or “shelter in place”. At this stage, we have no certainty as to how long the pandemic, or a more limited epidemic, will last, what regions will be most affected or to what extent containment measures will be applied.

Imaging centers are healthcare facilities and as such are generally considered an essential service and expected to continue to operate during any epidemic or pandemic. However, there is potential that actions taken by government, referring physicians or individual actions, in response to containment or avoidance of this coronavirus could impact a patient’s ability or decision to seek imaging services at a given time which could have a significant impact on volume at our imaging centers leading to temporary or prolonged staff layoffs, reduced hours, closures and other cost containment efforts. Further, there is potential that certain services which are not urgent and can be deferred without significant harm to a patient’s health may be delayed, either by the Company in response to local laws or good public health practice or voluntarily by the patient. In addition, there is potential that the outbreak of the coronavirus could impact supply chains, including the Company’s supply of personal protective equipment, and lead to personnel shortages, each of which could impact the ability of the Company to safely perform imaging services. It is also possible that social distancing efforts and sanitization and decontamination procedures could cause delays in the performance of imaging services. Depending on the severity and duration of the COVID-19 pandemic, there is potential for the Company to incur incremental credit losses beyond what is currently expected and potential future reduction in revenue and income and asset impairments.

12 Segmented financial information

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer. The Company has one reportable segment, which is outpatient diagnostic imaging services.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

13 Risk management arising from financial instruments

The carrying value of cash, accounts receivable, accounts payable and accrued liabilities and leases (current portion) approximates their fair value given their short-term nature.

The carrying value of the non-current portion of leases approximates their fair value given the difference between the discount rates used to recognize the liabilities in the condensed consolidated balance sheets and the normalized expected market rates of interest is insignificant. The estimated fair values of other non-current liabilities were as follows:

	September 30, 2020	December 31, 2019
	\$	\$
Amended May 2019 loans payable	372,502,600	360,596,500
Wesley Chapel Loan payable	1,216,100	1,483,830
Subordinated note – earn-out	200,000	184,485
ADG Acquisition – earn-out	9,377,106	14,834,067
Derivative financial instruments	4,905,863	951,105
	<u>388,201,669</u>	<u>378,049,987</u>

Financial instruments recorded at fair value on the condensed consolidated balance sheets are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities. As at September 30, 2020, the Company did not have any financial assets or liabilities measured at fair value under the Level 1 category.
- Level 2 – inputs other than quoted prices included in Level 1 that are observable for the asset or liability; either directly (i.e., as prices) or indirectly (i.e., derived from prices). As at September 30, 2020, the derivative financial instruments were measured at fair value under the Level 2 category on recognition. They are subsequently remeasured at fair value under the Level 2 category.
- Level 3 – inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Amended May 2019 Loans, Wesley Chapel Loan, Subordinated Note – Earn-out and ADG Acquisition – Earn-out were measured at fair value under the Level 3 category on recognition. The ADG Acquisition – Earn-out and Subordinated Note – Earn-out were subsequently remeasured at fair value under the Level 3 category (these liabilities were subsequently settled as discussed in note 6 and 9, respectively).

The following table summarizes information regarding the change in carrying value of the Company's financial instruments carried at fair value.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

	Derivative financial instruments \$	Subordinated Notes Earn-out \$	ADG Acquisition Earn-out \$
January 1, 2019	(16,014)	169,642	-
Issuance	-	-	14,748,022
Financial instruments revaluation loss (gain)			
Realized	-	-	-
Unrealized	967,119	14,843	86,045
December 31, 2019	951,105	184,485	14,834,067
Financial instruments revaluation loss (gain)			
Realized	-	-	-
Unrealized	3,954,758	15,515	(5,456,961)
September 30, 2020	4,905,863	200,000	9,377,106

There were no transfers between levels during the three and nine months ended September 30, 2020 and the twelve months ended December 31, 2019. A transfer is made between levels during the period that a financial instrument meets the relevant criteria.

Financial instruments are classified into one of the following categories: amortized cost, fair value through profit or loss and fair value through other comprehensive income.

The following table summarizes information regarding the carrying value of the Company's financial instruments:

	September 30, 2020 \$	December 31, 2019 \$
Cash	27,356,544	23,388,916
Accounts receivable	98,994,756	82,867,225
Financial assets measured at amortized cost	126,351,300	106,256,141
Accounts payable and accrued liabilities	32,340,619	26,262,225
Short-term portion of senior loans payable	4,380,668	3,705,952
Short-term portion of leases	12,378,388	11,066,293
Long-term portion of senior loans payable	340,732,549	336,276,370
Long-term portion of leases	138,492,268	126,399,101
Financial liabilities measured at amortized cost	528,324,492	503,709,941
Subordinated note – earn-out	200,000	184,485
ADG Acquisition – earn-out	9,377,106	14,834,067
Derivative financial instruments	4,905,863	951,105
Measured at fair value through profit or loss	14,482,969	15,969,657

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

14 Basic and diluted income (loss) per share

	Three-month period ended September 30, 2020 \$	Three-month period ended September 30, 2019 \$	Nine-month period ended September 30, 2020 \$	Nine-month period ended September 30, 2019 \$
Net income (loss) attributable to common shareholders	(1,550,121)	2,683,085	1,427,220	6,153,515
Weighted average common shares outstanding				
Basic	70,178,428	69,215,272	70,075,828	65,517,233
Add: additional shares issuable upon exercise of employee stock options, warrants and restricted share units	-	1,521,530	1,641,031	1,521,530
Diluted	70,178,428	70,736,802	71,716,859	67,038,763
Income (loss) per share Basic and diluted	(0.02)	0.04	0.02	0.09
Employee stock options warrants and restricted share units excluded from the computation of diluted per share amounts as their effect would be antidilutive	1,612,695	-	-	-

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

15 Revenue information

	Three-month period ended September 30, 2020 \$	Three-month period ended September 30, 2019 \$	Nine-month period ended September 30, 2020 \$	Nine-month period ended September 30, 2019 \$
Commercial	45,305,109	47,772,539	130,408,011	118,644,607
Medicare	7,945,049	7,337,169	22,044,270	20,083,513
Medicaid	2,291,811	1,891,924	6,169,196	5,472,208
Attorney	5,467,807	5,723,395	16,404,285	9,461,822
Workers comp	2,762,129	2,917,767	7,895,542	7,484,691
Other patient revenue	2,815,032	2,580,546	7,459,920	7,441,286
Service fees - net of allowances and discounts	66,586,937	68,223,340	190,381,224	168,588,127
Other revenue (management and ancillary fees and government grants)	537,503	650,592	2,706,419	1,822,142
	<u>67,124,440</u>	<u>68,873,932</u>	<u>193,087,643</u>	<u>170,410,269</u>

16 Cost of operations, excluding depreciation and amortization

	Three-month period ended September 30, 2020 \$	Three-month period ended September 30, 2019 \$	Nine-month period ended September 30, 2020 \$	Nine-month period ended September 30, 2019 \$
Employee compensation	21,373,254	23,793,719	62,071,836	60,457,981
Reading fees	9,507,254	9,475,721	27,853,567	24,242,249
Rent and utilities	7,065,939	7,109,620	22,884,290	18,800,137
Third party services and professional fees	5,396,226	5,121,945	16,502,804	12,637,341
Administrative	2,735,883	3,253,288	9,246,366	8,897,585
Medical supplies and other	2,774,893	2,091,514	7,983,930	5,881,389
	<u>48,853,449</u>	<u>50,845,807</u>	<u>146,542,793</u>	<u>130,916,682</u>

17 New accounting standards

The standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Company's consolidated financial statements are disclosed below. The Company intends to adopt these standards, if applicable, when they become effective.

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

ASU 2018-15, Intangibles – Goodwill and Other – Internal Use Software (Topic 350-40)

In August 2018, the FASB issued ASU 2018-15, *Intangibles – Goodwill and Other – Internal-Use Software (Topic 350-40)*. The ASU is intended to improve the recognition and measurement of financial instruments. The new guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. For all other entities, this ASU is effective for annual reporting periods beginning after December 15, 2020. The Company is considered an Emerging Growth Company as classified by SEC, which gives the Company relief in the timing of implementation of this standard by allowing the private company timing for adoption. The Company continues to evaluate the impact of the standard on its consolidated financial statements.

ASU 2016-13, Financial Instruments – Credit Losses (Topic 326)

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments*, and related clarifying standards, which replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to assess credit loss estimates. The ASU is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption permitted. For all other entities, this ASU is effective for fiscal years beginning after December 15, 2022. The Company is considered an Emerging Growth Company as classified by SEC, which gives the Company relief in the timing of implementation of this standard by allowing the private company timing for adoption. The Company continues to evaluate the impact of the standard on its consolidated financial statements.

18 CARES Act

- i) During April 2020, the Company received approximately \$1.1 million in grant under the first appropriation made by the U.S. Health and Human Services (HHS) to Medicare providers pursuant to the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). Subsequently, in December 2020, the Company received an additional grant from the HHS of approximately \$4 million. Additional grants may be available to the Company through subsequent appropriations under this program. The Company applied for these grants after determining that it was eligible to do so. Also, the Company has incurred expenses and experienced loss of revenue that are eligible to be reimbursed under these grants. The grants received are recorded in the condensed consolidated statements of operations and comprehensive income (loss) in the category “Other revenue”.
- ii) During April 2020, the Company received approximately \$3.1 million of accelerated Medicare payments under the expanded Accelerated and Advance Payments Program from Centers for Medicare & Medicaid Service (CMS). These payments are required to be applied to claims beginning one year after their receipt through the adjudication of Medicare claims over a future period. These payments to the Company are

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

recorded in the condensed consolidated balance sheets in the category "Accounts payable and accrued liabilities" until earned.

- iii) The CARES Act allows employers to defer the deposit and payment of the employer's share of Social Security taxes. As of September 30, 2020, such taxes were approximately \$1.5 million and are recorded in the condensed consolidated balance sheets in the category "Accrued payroll taxes".

19 Subsequent events

- i) On October 23, 2020, the Company paid \$200,000 to completely settle the Subordinated Note – Earn-out.
- ii) On November 2, 2020, the Company closed its previously announced offering of \$400 million of aggregate principal amount of 7.00% senior secured notes due November 1, 2025 (the 2025 Senior Notes). The net proceeds from this offering were used to repay in full, in accordance with respective contracts, the Amended May 2019 Term Loans and Revolving Facility and the net derivative financial instrument liabilities and to pay related financing fees and expenses. The balance has been retained as cash. The 2025 Senior Notes are fully and unconditionally guaranteed, jointly and severally, on a senior secured basis by the Company and each of its direct or indirect wholly owned subsidiaries, including the Revenue Practices and the guarantors.
- iii) Concurrently with the closing of the 2025 Senior Notes, the Company entered into a new revolving credit agreement (the November 2020 Revolving Credit Agreement) with BBVA USA, as administrative and collateral agent to provide for a senior secured revolving credit facility in an aggregate principal amount of \$55 million (the November 2020 Revolving Facility), with sub-limits for the issuance of letters of credit and for swingline loans. The November 2020 Revolving Facility is secured pari passu with the obligations under the 2025 Senior Notes. The November 2020 Revolving Facility will mature on the date that is five years after the issue date (the November 2020 Revolving Facility Maturity Date); provided that, if more than \$50 million in aggregate principal amount of notes is outstanding on the date that is 181 days prior to the November 2020 Revolving Facility Maturity Date, then the November 2020 Revolving Facility Maturity Date shall instead be the date that is 181 days prior to the November 2020 Revolving Facility Maturity Date.

The availability of borrowings under the November 2020 Revolving Facility is subject to customary terms and conditions.

- iv) On November 2, 2020, the Company reached a settlement with the sellers of its Georgia business pursuant to the process contemplated by the purchase agreement for that business which valued the ADG Acquisition - Earn-out at approximately \$9.4 million. In accordance with the terms of the purchase agreement between the parties, 50% of the value of ADG Acquisition - Earn-out (approximately \$4.7 million) was paid within 5 business days after the value was finally determined and the balance is to be paid 6 months thereafter, in May 2021.
- v) The Company announced on February 11, 2021 that it completed its private offering of \$75 million aggregate principal amount of additional 7.00% senior secured notes due November 2025 (the "New

Akumin Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2020

(expressed in US dollars unless otherwise stated)

Notes"). The New Notes were offered as additional notes under the same indenture as the previously issued 2025 Senior Notes and will be treated as a single series with the 2025 Senior Notes.

The Company expects to use the net proceeds from this offering for future acquisitions, with any unused proceeds to be used for working capital and other general corporate purposes, which may include reducing debt. The New Notes are fully and unconditionally guaranteed, jointly and severally, on a senior secured basis by each wholly owned subsidiary of the Company, including the Revenue Practices and the guarantors.

- vi) Effective March 1, 2021, the Company completed a common equity investment in an artificial intelligence business as part of a private placement offering for approximately \$4.6 million. The target develops artificial intelligence aided software programs for use in medical businesses, including outpatient imaging services of the sort provided by the Company. As a result of the investment, a previous investment in a convertible note instrument issued by the target to the Company in May 2020 converted for common equity. The Company's total investment is estimated to be valued at approximately \$8.0 million and represents a 34.5% interest in the target. In addition, the Company holds share purchase warrants which, subject to the occurrence of certain events, and the payment of approximately \$0.4 million, would entitle the Company to acquire a further 2.4% interest in the target's common equity.
- vii) On March 9, 2021, the Board granted 645,000 RSUs and 70,000 options to certain employees and consultants of the Company pursuant to the Company's RSU plan and stock option plan, respectively, in connection with the Company's equity bonus awards. In addition, 84,032 RSUs were granted to non-executive directors of the Company as part of their 2021 compensation and 50,000 RSUs were awarded as part of a signing bonus to an executive who started with the Company on March 29, 2021. Subject to and in accordance with the terms of the RSU plan, 50% of the RSUs granted will vest and settle for common shares one year after the date of grant and the remaining 50% will vest and settle for common shares two years after the date of grant. Subject to and in accordance with the stock option plan, the options were granted with an exercise price of \$3.58 per share, representing the 5-day volume weighted average price of the shares prior to the date of grant and an expiry date of 7 years after the date of grant. The options granted will vest as follows: 34% of the grant vest one year after the date of grant, 33% two years after the date of grant and the remaining 33% three years after the date of grant.